Objective: The incretins GLP-1 and GIP have been postulated to play a role in regulating insulin action although the mechanisms behind this relationship remain obscure. We used the hyperinsulinemic-euglycemic clamp to determine sites where insulin action may be modulated in double incretin receptor knockout (DIRKO) mice, which lack endogenous incretin action.
ollowing ingestion of a meal, multiple hormones are secreted from specialized enteroendocrine cells in the gut epithelium that coordinate events necessary for proper absorption and storage of nutrients. One such event is the control of glucose excursions and maintenance of glucose homeostasis following nutrient ingestion. Two gutderived incretin hormones, glucosedependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) play a significant role in this process by enhancing insulin secretion from pancreatic β-cells in response to oral nutrient intake (1, 2) . This incretin effect is mediated via activation of distinct G protein-coupled receptors for GIP (GIPR) and GLP-1 (GLP-1R) in β-cells, which initiates signaling cascades necessary for glucose-dependent insulin secretion (1) .
GIP and GLP-1 also regulate glucose homeostasis via actions independent of insulin secretion. Activation of the incretin receptors stimulate pathways that enhance β-cell proliferation and inhibit β-cell apoptosis (3) (4) (5) (6) (7) . GLP-1 inhibits glucagon secretion from pancreatic α-cells and delays gastric emptying, thus preventing large excursions in blood glucose levels (8) (9) (10) . GLP-1 may also exert control on hepatic glucose production and peripheral glucose clearance independent of its effects on insulin secretion (11, 12) . GIP has been shown to stimulate insulin-mediated glucose uptake and lipoprotein lipase activity in cultured adipocytes (13) .
Mice lacking either GIPR or GLP-1R exhibit only mild glucose intolerance due to impaired glucose-stimulated insulin secretion (14) (15) (16) (17) (18) (19) . The absence of a more severe phenotype is likely due to compensatory increases in the circulating levels of and/or sensitivity to the remaining incretin hormone. For example, disruption of GLP-1R results in increased circulating levels of and enhanced sensitivity to GIP (20) . Similarly, although GLP-1 levels do not increase in mice lacking GIPR, these mice exhibit enhanced sensitivity to GLP-1 action (21) .
In order to understand the consequences of complete loss of incretin receptor signaling, double incretin receptor knockout (DIRKO) mice have been generated.
Despite a complete absence of endogenous GIP and GLP-1 action, DIRKO mice exhibit only moderate glucose intolerance compared to single incretin receptor knockout mice (22, 23) . In spite of the metabolic stress imposed by chronic high fat feeding, DIRKO mice chronically fed a HF diet exhibit only a modest deterioration in glucose tolerance, together with resistance to diet-induced obesity and increased energy expenditure and locomotor activity (24) . The aims of the present studies are to a) assess the effects of a complete disruption of incretin signaling on insulin action in regular chow-fed mice and b) determine whether the lack of incretin signaling impairs the normal compensatory mechanisms arising in HFfed mice. These aims were addressed using the hyperinsulinemic-euglycemic clamp, a technique that allows for the assessment of insulin action in conscious, unrestrained mice.
RESEARCH

DESIGN AND METHODS
Mouse maintenance and genotyping. All procedures were approved by the Vanderbilt Animal Care and Use Committee.
Double incretin receptor knockout (DIRKO) mice on a CD1 background were backcrossed onto a F C57BL/6 background (at least 10 generations) and bred to C57BL/6 mice (Jackson Laboratories) to obtain double incretin receptor heterozygous founder mice. A heterozygous breeding pair was then used to generate wild-type (WT) and DIRKO breeding pairs, such that all subsequent WT and DIRKO mice used in these studies originated from the same heterozygous founder breeding pair. Littermates were weaned and separated by sex at 3 weeks of age. Genotyping was done by polymerase chain reaction of genomic DNA obtained from a tail biopsy. All mice were fed either regular chow (Purina 5001, Purina Mills) or high fat (HF) diet (F-3282, Bio-Serv) ad libitum, were handled at least once per week, and were studied at ~4 months of age. Regular chow diet contains 12.1% calories from fat, while HF diet contains 59.4% calories from fat. Assessment of body composition, feeding and energy expenditure. Body composition was determined at ~4 months of age using an mq10 NMR analyzer (Bruker Optics).
For food intake assessment, mice were placed in individual cages with measured amounts of food and bedding. The remaining food was weighed 48h later, excluding fecal matter and bedding. Oxygen consumption (VO 2 ) and carbon dioxide production (VCO 2 ) were measured using an Oxymax indirect calorimetry system (Columbus Instruments) as described previously (25) . Energy expenditure was calculated as described previously (25, 26) . Respiratory exchange ratio (RER) was calculated as VCO 2 /VO 2 . Ambulatory activity was estimated by the number of infrared beams broken in both X and Y directions. Assessment of fat absorption. Following 8 weeks of HF feeding, 20 week old male WT and DIRKO mice (n=5/group) were placed in individual cages with no bedding and provided with a pre-weighed amount of HF food. Every 24h for 3 days, cages were changed, food was weighed and total feces were collected. Upon completion of the collection phase, feces were completely dried to constant weight using a speed-vac at 60°C for 1h. The mass of excreted feces was measured, and fat extraction was conducted on equal amounts of feces for both groups following the Nelson and O'Hopp method (27) with minor modifications. Briefly, feces were rigorously mixed in one volume of chloroform/methanol (1:2) and 2 volumes of 5N HCl and incubated overnight in the dark at room temperature. Following centrifugation for 30min at 4,000rpm the organic phase was collected into pre-weighed tubes. The chloroform was evaporated and tubes were reweighed to calculate fecal fat content. Hyperinsulinemic-euglycemic clamps. Mice were catheterized at least 5 days prior to experimentation as described previously (28) .
Hyperinsulinemiceuglycemic clamps were performed on 5h-fasted mice (28) . A 5 µCi bolus of [3-3 H] glucose was given at t = -90 min prior to insulin infusion, followed by a 0.05 µCi/min infusion for 90 min. Blood samples were obtained via an arterial catheter (28) . Basal glucose specific activity was determined from blood samples at t = -15 and -5 min. Fasting insulin levels were determined from blood samples taken at t = -5 min. The clamp was begun at t = 0 min with a continuous infusion of human insulin ( 
Isolation of whole-cell extracts and immunoblotting.
Liver and muscle (gastrocnemius) tissue (20-40 mg) was homogenized in 10 µL/mg tissue extraction buffer (50 mM Tris, 1mM EDTA, 1mM EGTA, 10% glycerol, 1% Triton-X 100, pH 7.5) supplemented with protease (Pierce) and phosphatase (Sigma) inhibitor cocktails. Homogenates were centrifuged (20 min, 4500g, 4°C), pellets were discarded, and supernatants were retained for protein determination. Protein content was determined using a BCA protein assay kit (Bio-Rad). Whole-cell (20 µg) extracts were separated on 10% Bis-Tris SDS-PAGE gels (Invitrogen), followed by electrophoretic transfer to polyvinylidine fluoride membranes. Primary antibodies were incubated with the membranes overnight at 4 o C. Secondary antibodies were incubated at room temperature for 1h. Imaging and densitometry were performed using the Odyssey imaging system (Li-Cor). Rabbit anti-Akt (1:1000) and antiphospho(Ser473)-Akt (1:1000) were from Cell Signaling.
Mouse anti-GAPDH (1:2000) was from Abcam. Calculations. Glucose appearance (R a ) and disappearance (R d ) were determined using Steele nonsteady-state equations (29) . Endogenous glucose production (endoR a ) was determined by subtracting the glucose infusion rate (GIR) from total R a . Glucose metabolic index (R g ) was calculated as previously described (25, 30, 31) . R g for all tissues was normalized to brain R g . Statistical analysis. Data are presented as means ± SEM. Differences between groups were determined by two-way ANOVA followed by Tukey's post hoc tests or by one-tailed t test as appropriate. The significance level was P < 0.05.
RESULTS
DIRKO mice exhibit decreased weight
gain and fat mass due to increased energy expenditure and activity. DIRKO mice on a C57BL/6 background and wildtype (WT) mice were placed on a regular chow or a high-fat (HF) diet for 12 weeks beginning at 3 weeks of age. DIRKO mice had decreased weight gain associated with reduced muscle mass compared to WT mice on a chow diet ( Figure 1 and Table 1 ). HF feeding resulted in increased weight gain in WT mice ( Figure 1 ) associated with increased fat and muscle mass (Table 1 ).
In contrast, HF feeding did not affect weight gain in DIRKO mice ( Figure 1 ) and resulted in only a small increase in fat mass (Table 1) .
Energy expenditure normalized to total body weight was increased in DIRKO mice compared to WT on both chow and HF diets (Figures 2A and 2B ). DIRKO mice on HF diet also exhibited higher light-cycle energy expenditure than DIRKO mice on chow diet. When normalized to lean body mass, energy expenditure was increased in DIRKO mice compared to WT mice on chow but not on HF diet ( Figure 2D ). Respiratory exchange ratio (RER) was also not different between WT and DIRKO mice on either diet ( Figure 2E ). Energy intake was not different between WT and DIRKO mice on either diet ( Figure 2F ). Light-cycle ambulatory activity was increased in chow-fed, but not HF-fed, DIRKO mice compared to WT mice ( Figure 2G) .
Conversely, dark-cycle ambulatory activity was higher in HF-fed, but not chow-fed, DIRKO mice compared to WT mice ( Figure 2G ). HF-fed DIRKO mice did not exhibit defective fat absorption, as fat intake and excretion were normal compared to HF-fed WT mice ( Figure 3 ).
Chow-and HF-fed DIRKO mice exhibit enhanced whole-body insulin action.
Insulin action was assessed in chow-fed, conscious, unrestrained WT and DIRKO mice using the hyperinsulinemic (4 mU·kg -1 ·min -1 )-euglycemic clamp. Fasting (5h fast) glucose and insulin levels were not different between WT and DIRKO mice ( Figure 4A , top panel and Table 2 ). Fasting non-esterified fatty acids (NEFAs) were lower in DIRKO mice ( Table 2 ). Arterial glucose was clamped at similar levels in both groups ( Figure 4A, top panel) . The glucose infusion rate (GIR) necessary to maintain euglycemia was not different between groups ( Figure 4A , bottom panel). However, clamp insulin levels were lower in DIRKO mice (Table 2) .
Thus, normalizing GIR to clamp insulin levels, an index of insulin sensitivity, shows enhanced insulin action in DIRKO mice (Table 2) . Insulin-mediated suppression of endoR a and stimulation of R d was not different between WT and DIRKO mice ( Figure 5 ), although insulin levels were lower in the latter. Clamp NEFAs were significantly lower in DIRKO mice ( Table  2 ). The ability of insulin to suppress NEFAs was not different between WT and DIRKO mice, as shown by the change in NEFAs normalized to the change in insulin from fasting to clamp levels ( Table  2) .
Insulin action was also assessed in HF-fed WT and DIRKO mice. Fasting glucose and insulin levels were markedly higher in HF-fed WT than DIRKO mice ( Figure 4B , top panel and Table 2 ). Compared to chow-fed mice, fasting insulin and glucose levels were higher in HF-fed WT mice, indicative of fasting insulin resistance. By contrast, HFfeeding had no effect on fasting glucose in DIRKO mice but resulted in markedly lower fasting insulin levels ( Table 2) . As in chow-fed mice, fasting NEFAs were lower in HF-fed DIRKO mice, even though fasting insulin levels were markedly lower in this group (Table 2) . Arterial glucose was clamped at similar levels in both HF-fed WT and DIRKO mice ( Figure 4B, top panel) . The GIR necessary to maintain euglycemia was significantly lower in WT mice ( Figure  4B , bottom panel), even as clamp insulin levels were higher in this group (Table 2) . Thus, normalizing GIR to clamp insulin levels shows HF-fed DIRKO mice to have a >3-fold higher index of insulin sensitivity than WT mice (Table 2) . Furthermore, DIRKO mice are protected from HF diet-induced insulin resistance, since HF feeding resulted in a >3-fold decrease in insulin sensitivity in WT mice, whereas insulin sensitivity was insignificantly decreased in DIRKO mice (Table 2) . Clamp NEFAs were also significantly lower in DIRKO mice ( Table  2) . As in chow-fed mice, suppression of NEFAs by insulin was not different between HF-fed WT and DIRKO mice ( Table 2) .
Insulin-mediated suppression of endoR a was not significantly different between HF-fed WT and DIRKO mice, although insulin levels were drastically lower in the latter group (Figures 5A and 5B). Compared to chow feeding, HF feeding resulted in impaired suppression of endoR a in WT but not in DIRKO mice ( Figure 5B ). Despite lower clamp insulin levels in DIRKO mice, stimulation of R d was significantly higher in this group ( Figures 5C and 5D) . Furthermore, while the stimulation of R d was inhibited in HFfed WT mice, this inhibition did not occur in DIRKO mice.
Cardiac glucose uptake is enhanced in chow-fed DIRKO mice. A bolus of 2[
14 C]deoxyglucose was administered during the clamp to determine the glucose metabolic index (R g ), a measure of tissue glucose uptake. Absolute R g in skeletal muscle was lower in chow-fed DIRKO mice compared to WT mice, as shown in gastrocnemius and superficial vastus lateralis (SVL) muscles ( Figure 6A ). However, when normalized to clamp insulin levels, R g in these muscles was not different between groups ( Figure 6C ). Absolute R g was not affected in oxidative muscles, such as soleus, diaphragm, and heart ( Figures 6A and 6B) . When normalized to clamp insulin levels, R g in the heart was increased in DIRKO compared to WT mice ( Figure 6D ). DIRKO mice are protected from HF dietinduced impairments in insulinstimulated muscle glucose uptake. Absolute R g was significantly higher in all muscles analyzed from HF-fed DIRKO compared to WT mice, except for soleus and gastrocnemius ( Figures 6A and 6B) . However, when normalized to clamp insulin levels, R g was higher in all muscles from HF-fed DIRKO mice ( Figures 6C and 6D ). The lack of incretin receptors also prevented the HF dietinduced decrease in muscle R g observed in WT mice. HF feeding did result in decreased heart R g normalized to clamp insulin levels in DIRKO mice, although not to the degree observed in WT mice ( Figure 6D ). DIRKO mice exhibit enhanced liver and muscle insulin signaling. To determine whether the enhanced insulin action in both chow-and HF-fed DIRKO mice was associated with enhanced insulin signaling, Akt activation, defined as the ratio between phosphorylated (Ser473) Akt and total Akt, was assessed in liver and gastrocnemius muscle. Total gastrocnemius Akt protein levels were not different between WT and DIRKO mice on either chow or HF diets ( Figures 7A  and 7B ). Gastrocnemius Akt activation was significantly higher in DIRKO mice on HF but not on chow diet ( Figure 7C ). Total liver Akt protein was significantly lower in DIRKO mice on chow or HF diet compared to WT mice ( Figures 7D and  7E) . However, liver Akt activation was significantly enhanced in DIRKO mice fed either diet compared to their WT counterparts ( Figure 7F ).
DISCUSSION
In the present studies, the hyperinsulinemic-euglycemic clamp was used to delineate specific sites where insulin action may be affected by deletion of the receptors for the incretin hormones, GLP-1 and GIP. Furthermore high fat (HF) feeding for 12 weeks was used to precipitate phenotypes associated with the lack of incretin receptor signaling that would otherwise be silent in chow-fed mice. Compared to wild-type (WT) mice, double incretin receptor knockout (DIRKO) mice exhibit increased energy expenditure when fed either a chow or a HF diet due, at least in part, to increased locomotor activity. Consequently, chowfed DIRKO mice have reduced weight gain due to decreased muscle mass. HFfed DIRKO mice have reduced weight gain due to decreased fat mass compared to HF-fed WT mice. Here we show that DIRKO mice exhibit enhanced insulin sensitivity on either chow or HF diets. Chow-fed DIRKO mice have decreased insulin levels but demonstrate equal glucose infusion rates (GIR), suppression of hepatic glucose production (endoR a ) and stimulation of glucose disappearance (R d ) during a hyperinsulinemiceuglycemic clamp. Moreover, DIRKO mice are protected from HF diet-induced insulin resistance as shown by lower fasting glycemia and insulinemia and higher GIR, suppression of endoR a , R d , and R g during a clamp than HF-fed WT mice. This effect on insulin action was associated with enhanced insulin signaling at both the liver and muscle. Thus, these results demonstrate a role for incretin receptor signaling in the control of insulin action.
A recent study by Hansotia et. al. showed increased energy expenditure associated with increased ucp-1 gene transcription and greater locomotor activity in both DIRKO mice and mice lacking GLP-1R (24) . GLP-1R knockout mice have decreased weight gain on a HF diet, although this was only observed in female mice (18) . GIPR knockout mice are also protected from HF diet-induced obesity due to increased fat oxidation and energy expenditure (13) . This was also observed in a model of genetic obesity, the ob/ob mouse, crossed with GIPR knockout mice (13) .
In the present studies, increased energy expenditure in both chow-and HF-fed DIRKO mice was associated with increased locomotor activity, but the lack of an effect on the respiratory exchange ratio (RER) suggests that fat oxidation was not increased in DIRKO mice. However, NEFA levels were lower in DIRKO mice on either chow or HF diets, even as insulin levels were also lower. Thus, an effect of disrupted incretin signaling on increased fat oxidation cannot be ruled out. Fat absorption was also not impaired in HFfed DIRKO mice, as the percent of ingested fat excreted in the feces was not different compared to WT mice.
The results obtained from the present studies are interesting in that a mutation that impairs β-cell function also preserves insulin sensitivity. This is especially evident in the presence of a metabolic stressor, such as HF feeding.
WT mice respond to chronic HF feeding by significantly increasing β-cell area, islet number, and pancreatic insulin content, and are more insulin resistant. Hansotia et. al. (24) showed that, in response to chronic HF feeding, β-cell area and islet number are increased in DIRKO mice, although not to the degree observed in WT mice. Unlike WT mice on HF diet, pancreatic insulin content in HF-fed DIRKO mice is not increased (24) , resulting in significantly lower fasting insulin levels, as shown in the present studies. However this impaired morphological and functional pancreatic response to HF feeding in DIRKO mice is offset by preservation of hepatic and peripheral insulin sensitivity.
Obesity is a significant risk factor associated with the development of insulin resistance and type 2 diabetes (32,33). Thus, decreased obesity is likely associated with protection from HF dietinduced insulin resistance in DIRKO mice. Consistent with this, chemical ablation of GIPR with (Pro 3 )GIP, a GIPR antagonist, has been shown to decrease adiposity, improve glucose tolerance, and modestly enhance the response to intraperitoneal insulin in ob/ob mice (34) . Similarly, tissue lipid accumulation is reduced and the glucose response to an intraperitoneal insulin injection is preserved in HF-fed GLP-1R knockout and DIRKO mice compared to HF-fed WT mice (24) . In order to directly address the effect of a disruption in incretin signaling on insulin action, the present studies utilized the hyperinsulinemic-euglycemic clamp in conscious, unrestrained mice. This technique is generally considered the "gold standard" for assessment of in vivo insulin action. The addition of isotopic glucose tracers with this technique allows for the determination of specific sites where insulin action is affected. While HF feeding impairs insulin-mediated suppression of endoR a and stimulation of R d in WT mice, these impairments do not occur in HF-fed DIRKO mice. Indeed, DIRKO mice on a HF diet have a >3-fold higher index of insulin sensitivity (GIR/[Insulin]) than HF-fed WT mice. Furthermore, R g is impaired in WT mice fed a HF diet, whereas DIRKO mice do not exhibit such a diet-induced impairment. This protection from HF diet-induced insulin resistance in DIRKO mice is associated with enhanced insulin signaling, as both hepatic and muscle Akt activation is greater in HF-fed DIRKO mice compared to their WT counterparts.
Recent evidence indicates that GLP-1 action in the brain can acutely regulate peripheral insulin sensitivity. Knauf et. al. showed that glucose requirements during a hyperinsulinemichyperglycemic clamp are higher in mice receiving an icv infusion of the GLP-1R antagonist exendin 9-39 (35) . Conversely, mice receiving the GLP-1R agonist exendin 4 directly into the brain showed decreased glucose requirements.
2-deoxyglucose uptake into skeletal muscle was increased in mice receiving icv exendin 9-39 and decreased in mice receiving exendin 4 under hyperinsulinemic-hyperglycemic conditions. These studies suggest that endogenous GLP-1 action in the brain inhibits muscle insulin action. Thus, in agreement with the present studies, the disruption of central GLP-1 action enhances peripheral insulin sensitivity.
Phenotypes associated with insulin action were also observed in chow-fed DIRKO mice. Absolute R g in three different skeletal muscles was lower in DIRKO than WT mice. However, when normalized to clamp insulin levels, there was no difference in muscle R g between these two groups.
Interestingly, Akt protein expression in the gastrocnemius was lower in DIRKO mice, but Akt activation was higher. This was evident even as clamp insulin levels were lower in DIRKO mice. R g in the heart was also higher in DIRKO compared to WT mice. This is likely due to loss of GLP-1R signaling, as this incretin receptor, and not GIPR, is expressed in the heart (36, 37) . DIRKO mice exhibited lower fasting NEFA levels on both chow and HF diets, even as fasting insulin levels were insignificantly lower in chow-fed mice and significantly lower in HF-fed mice. Activation of GIPR in cultured 3T3-L1 adipocytes stimulates heparin-releasable lipoprotein lipase activity, increasing NEFA levels (13) . Thus, disruption of GIPR signaling in adipocytes likely results in decreased fasting NEFA levels in DIRKO mice.
Although insulinmediated suppression of NEFA levels was equal in WT and DIRKO mice, we cannot rule out a direct effect of disrupting incretin signaling on lipid turnover.
Taken together, these studies demonstrate that although complete disruption of incretin receptor signaling results in impaired β-cell function and adaptation to chronic HF feeding (24) , this is overcome by preservation of insulin action. This is likely secondary to effects on energy expenditure, activity and adiposity associated with the lack of incretin receptor signaling. While disruption of GIPR results in impaired β-cell function, it also results in increased energy expenditure and decreased adiposity.
Similarly, the deleterious effects of ablating GLP-1R signaling on β-cell function are overcome by increased activity-dependent energy expenditure. Thus, the absence of incretin receptor signaling results in a metabolic status capable of responding to impaired β-cell function and the stress of HF feeding. These results extend the importance of incretin action in regulating glucose homeostasis beyond the pancreas and demonstrate how incretin receptor signaling can modulate insulin action by mechanisms other than stimulation of insulin secretion. 
ACKNOWLEDGMENTS
